Investor Relations, Latest News, Angina Hemostemix Adds the treatment of Refractory Angina to its Phase 1 Basket Protocol Read More
Hemostemix Files FDA Submission for Basket Protocol (Filing 1517) to Advance ACP-01 (VesCell™) Across Multiple Ischemic and Vascular Indications Simultaneously Read More
Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company Read More
